Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Mexico | es
  • United States | en
  • Venezuela | es
  • Australia | en
  • Bangladesh | en
  • Hong Kong S.A.R. | zh
  • India | en
  • Indonesia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Malaysia | en
  • Pakistan | en
  • Philippines | en
  • Singapore | en
  • Taiwan | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hungary | hu
  • Ireland | en
  • Italy | it
  • Latvia | lv
  • Lithuania | lt
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Egypt | en
  • Israel | he
  • South Africa | en
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Bangladesh | en
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Central America | es
  • Colombia | es
  • Czech Republic | cs
  • Czech Republic | en
  • Denmark | da
  • Egypt | en
  • Estonia | et
  • Finland | fi
  • France | fr
  • Germany | de
  • Greece | el
  • Hong Kong S.A.R. | zh
  • Hungary | hu
  • India | en
  • Indonesia | en
  • Ireland | en
  • Israel | he
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Latvia | lv
  • Lithuania | lt
  • Mainland China | zh
  • Malaysia | en
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Novartis Foundation | en
  • Pakistan | en
  • Philippines | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Serbia | sr
  • Singapore | en
  • Slovakia | sk
  • South Africa | en
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Taiwan | zh
  • Turkey | tr
  • United Kingdom | en
  • United States | en
  • Venezuela | es
    • About
      • Board of Directors
        • Joerg Reinhardt
        • Simon Moroney
        • Nancy Andrews
        • Ton Buechner
        • Patrice Bula
        • Elizabeth Doherty
        • Ana de Pro Gonzalo
        • Bridgette Heller
        • Daniel Hochstrasser
        • Frans van Houten
        • Andreas von Planta
        • Charles Sawyers
        • William Winters
        • Charlotte Pamer-Wieser
      • Executive Committee
        • Vasant Narasimhan
        • Shreeram Aradhye
        • James Bradner
        • Victor Bulto
        • Aharon (Ronny) Gal
        • Karen Hale
        • Harry Kirsch
        • Rob Kowalski
        • Steffen Lang
        • Klaus Moosmayer
        • Richard Saynor
        • Marie-France Tschudin
        • Lutz Hegemann
        • Michael Willi
        • Kees Roks
      • Strategy
        • People and Culture
        • Data and Digital
      • Products
      • Innovative Medicines
      • Sandoz
      • Diversity & Inclusion
        • Equity
        • Diversity & Inclusion Governance and Community
        • Inclusivity
        • Parental Leave
        • Society
      • Manufacturing
      • Quality
        • Audit program
        • Novartis Quality Management System (QMS)
        • Product and patient safety training
        • Regulatory inspections
        • Product recalls
        • Third-party suppliers
      About Novartis
    • Patients and Caregivers
      • Novartis Commitment to Patients and Caregivers
      • Diseases
      • Patient Organization Funding
      • Adverse Event Reporting
      • COVID-19: Patients and Caregivers
      • Stories: Patients Perspectives
      Patients & Caregivers
    • Healthcare Professionals
      • Medical Congresses and Events
        • Abstract summaries for EULAR
        • Abstract summaries for ACR
        • Abstract summaries for EADV
      • Products
      • Novartis Pipeline
      • Managed Access Programs
        • Novartis Gene Therapies Managed Access Program
      • Novartis External Funding
      • Healthcare Professional Resources by Country
      • Investigator-Initiated Trials / Studies
      • Transparency and Disclosure
      • Novartis Medical Information
        • Submit medical enquiry
      Healthcare Professionals
    • Research & Development
      • Novartis Institutes for BioMedical Research
        • Collaborations
        • NIBR Global Scholars Program
      • Technology Platforms
        • Radioligand Therapy
        • Gene Therapy
        • Cell Therapy
      • Research Disease Areas
        • Immuno-oncology research at Novartis
        • Oncology research at Novartis
        • Cardiovascular and metabolic disease research at Novartis
        • Autoimmunity, transplantation and inflammatory disease research at Novartis
        • Ophthalmology research at Novartis
        • Neuroscience Research at Novartis
        • Musculoskeletal Disease Research at Novartis
        • DAx: exploratory disease research at Novartis
      • Research Locations
        • Novartis Institute for Tropical Diseases
      • Novartis Pipeline
      • Translational Medicine
      • Research & Development Approach
      • Research Collaborations
      • Open Source Science
      • Stories from our Labs
      Research & Development
    • ESG
      • Access
        • Creating sustainable business models
        • Value-Based Pricing
        • Sub-Saharan Africa
        • Donations
        • Novartis Access Principles
        • Novartis Oncology Access
        • Patents and Licensing
      • Ethics, Risk and Compliance
        • Ethical Behavior
        • Compliance
        • Human Rights
        • Learning and Engagement
        • Risk management
      • Environmental Sustainability
        • Climate
        • Waste
        • Water
      • Global Health
        • Anti-Microbial Resistance (AMR)
        • Avoidable Blindness
        • Chagas Disease
        • Leprosy
        • Malaria
        • Sickle Cell Disease (SCD)
        • Novartis Foundation
      • Diversity & Inclusion
      • Reporting
        • ESG Rating Performance
        • Codes, Policies and Guidelines
        • Materiality Assessment
        • Transparency and Disclosure
        • Targets
        • Positions
      • ESG Index
      Environmental, Social and Governance
    • Investors
      • Event Calendar
      • Financial Data
        • Novartis Annual Results
        • Novartis Quarterly Results
        • Novartis SEC Filings
        • Product Sales
        • Fixed-Income Securities
        • Expected Currency Impact
      • Share Data & Analysis
        • Share Monitor
        • Dividend Information
        • Share Ownership
        • Share Overview
      • Shareholder Information
        • General Meetings
        • American Depository Receipts (ADR)
        • Share Buy-Back
        • Frequently Asked Questions
      • Company Overview
        • Corporate Governance
      • Novartis Annual Reporting Suite
        • Reporting Archive
        • Publications Order Form
      • ESG
      Investors
    • News
      • News Archive
      • Media Library
      • Stories
      • Subscribe
      News
    • Careers
      • Career Search
      • Our Teams
        • Careers in Commercial
        • Careers in Communications and Advocacy
        • Careers in Consulting
        • Careers in Digital
        • Careers in Health, Safety & Environment
        • Careers in Information Technology (IT)
        • Careers in Medical & Development
        • Careers in People & Organization
        • Careers in Procurement
        • Careers in Research
        • Careers in Strategy
        • Careers in Manufacturing and Supply
        • Ethics, Risk & Compliance (ERC)
        • Careers in Legal
      • Career Programs
        • Community Exploration & Learning Lab (CELL)
      • Early Talent
      • Postdoc Program
        • Andreas Bender, PhD
        • Boxun Lu, PhD
        • The Novartis Innovation Postdoctoral Fellowship
        • The Novartis Discovery Postdoctoral Fellowship
        • Postdoc Research Themes
        • Recognition
        • Postdoc Program Leadership
      • International Careers
      • Personal Growth
      • Well-being
      • Internship Programs
      Careers
    • COVID-19 Information Center
      COVID-19 Novartis response
    • Clinical Trials
      Clinical Trials
    • Partnering
      Partnering
    • Contacts
      Contacts
    Home
  • Novartis completes tender offer for all outstanding shares of The Medicines Company
    Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), for all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ: MDCO…
    Targeted TherapyInnovationHeart FailureChronic IllnessAd Hoc
  • Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
    Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that it has completed the acquisition of The Medicines Company (the “Company”) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company surviving the merger, without…
    Targeted TherapyInnovationHeart FailureChronic Illness
  • Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
    Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for Japanese patients:
    RespiratoryReimagine MedicineOncologyNeuroscienceInnovationHeart Failure
  • Patient Perspectives
    Surviving with heart failure

    Heart failure affects 26 million people worldwide. Half die within five years of diagnosis. There's been a lack of progress in finding more effective medications. Advances in understanding mean new options for patients and caregivers.

    Chronic IllnessHeart Failure
  • Patient Perspectives
    Most Europeans have limited awareness about heart failure

    The majority of Europeans can’t identify the warning signs of heart failure, a life threatening disease, which affects one in five people in the region.

    Disease AwarenessHeart FailureLiving With DiseasePatient Education
  • Patient Perspectives
    Living with HFpEF – a patient’s story

    Cynthia lives with Heart Failure with preserved Ejection Fraction, a complex and challenging condition.

    Disease AwarenessDiseasesHeart FailureMedical InnovationsDrug Development
  • Patient Perspectives
    Living with heart failure

    Heart failure affects 26 million people worldwide. More people die from heart failure than from some advanced cancers, including breast and bowel cancer.

    Chronic IllnessHeart FailureLiving With DiseasePatient Education
  • Patient Perspectives
    Heart failure: coping with one of the world’s biggest killers

    Patients are learning to live with a chronic disease that will affect one in 5 people over age 40.

    Chronic IllnessHeart FailureLiving With Disease
  • Patient Perspectives
    Caring for someone with heart failure

    Caring for someone with heart failure can be both demanding and rewarding. Learn about the impact of being a carer and the support that carers need.

    Disease AwarenessDiseasesHeart FailurePatient VoicesDrug Development
  • Patient Perspectives
    AI Nurse evolving for heart failure patients in China

    Improved versions of our new digital platform for heart failure disease management in China have been developed since April, 2020 rollout.

    Chronic IllnessDigitalHeart Failure
  • Access to Healthcare
    Bringing Chagas disease to people’s attention

    Explaining Chagas disease through the stories of patients in Bolivia.

    Access to HealthcareHeart FailureInfectious Diseases
  • From Our Labs
    Women in Science: Jennifer Allport-Anderson

    Cardiovascular researcher Jennifer Allport-Anderson describes the personal qualities and decisions that have made her a successful leader.

    Heart FailureNovartis Institutes for BioMedical ResearchWomen in ScienceWorking at NovartisCareers

Pagination

  • 1
  • 2
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • COVID-19 Info Center
  • ESG
Explore
  • Stories
  • Diseases
  • Locations
  • Products
  • Novartis Pipeline
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2022 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience